A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma.
OBJECTIVE
To determine the long term efficacy of monotherapy with topically applied beta blocking agents and to determine whether selective beta blockers were able to preserve the visual field more effectively than non-selective agents.


METHODS
A prospective randomised, open, comparative study of three topically applied beta blockers-timolol, betaxolol, and carteolol-was carried out on 153 patients (280 eyes) with newly diagnosed open angle glaucoma. Those patients who were not withdrawn were followed by the same observers for a minimum of 2 years and a maximum of 7 years, with clinical observations, Goldmann tonometry and 24.2 Humphrey visual field analysis.


RESULTS
All three drugs lowered the IOP significantly from untreated levels but betaxolol took up to 12 months in some instances to reach the maximum pressure reduction. After 7 years only 43% of the eyes begun on timolol, 34% of those started on carteolol, and 29% of those on betaxolol were still being treated with these medications alone. Visual fields were analysed throughout the trial by CPSD and MD and at the end by linear regression analysis (PROGRESSOR). The visual fields remained the same without apparent improvement or deterioration throughout the period of follow up. Eight patients (11 eyes) were withdrawn because of continuing field loss in spite of reduction in IOP (six using carteolol and five using betaxolol).


CONCLUSIONS
Analysis shows that less than half the eyes initially treated with topical beta blockers might be expected to still be being treated with their original medication after 5 years. The rest required either additional medication or trabeculectomy. There was no statistically significant improvement or deterioration in the visual fields over a 7 year period. On the evidence of this trial there are no particular advantages in using selective beta blockers.
Watson
P G
PG
University of Leiden, Netherlands.
Barnett
M F
MF
Parker
V
V
Haybittle
J
J
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D015784:Betaxolol / Q000627:therapeutic use*; D002354:Carteolol / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D016014:Linear Models; D008297:Male; D011446:Prospective Studies; D016019:Survival Analysis; D013999:Timolol / Q000627:therapeutic use*; D014130:Trabeculectomy; D016896:Treatment Outcome; D014794:Visual Fields / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D013999:Timolol; D002354:Carteolol; D015784:Betaxolol